Vigamox (Moxifloxacin Alcon) Augndropar, lausn 5 mg/ml Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

vigamox (moxifloxacin alcon) augndropar, lausn 5 mg/ml

novartis healthcare a/s - moxifloxacinum hýdróklóríð - augndropar, lausn - 5 mg/ml

Ciflox (Ciproxin-Hydrocortison) Eyrnadropar, dreifa 2 mg + 10 mg/ml Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

ciflox (ciproxin-hydrocortison) eyrnadropar, dreifa 2 mg + 10 mg/ml

novartis healthcare a/s - ciprofloxacinum hýdróklóríð; hydrocortisonum inn - eyrnadropar, dreifa - 2 mg + 10 mg/ml

Maxidex Augndropar, dreifa 1 mg/ml Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

maxidex augndropar, dreifa 1 mg/ml

novartis healthcare a/s - dexamethasonum fosfat - augndropar, dreifa - 1 mg/ml

Maxitrol Augndropar, dreifa Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

maxitrol augndropar, dreifa

novartis healthcare a/s - neomycinum súlfat; polymyxinum b súlfat; dexamethasonum fosfat - augndropar, dreifa

Tobradex Augndropar, dreifa Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

tobradex augndropar, dreifa

novartis healthcare a/s - dexamethasonum fosfat; tobramycinum inn - augndropar, dreifa

Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics

novartis vaccines and diagnostics s.r.l. - yfirborðs mótefna gegn inflúensuveiru (haemagglutinin og neuraminidasa) á stofn a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - bóluefni - virkt bólusetning gegn h5n1 undirgerð inflúensu a veiru. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Myfortic Magasýruþolin tafla 180 mg Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

myfortic magasýruþolin tafla 180 mg

novartis healthcare a/s - mycophenolatum natríum - magasýruþolin tafla - 180 mg

Myfortic Magasýruþolin tafla 360 mg Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

myfortic magasýruþolin tafla 360 mg

novartis healthcare a/s - mycophenolatum natríum - magasýruþolin tafla - 360 mg

Icandra (previously Vildagliptin / metformin hydrochloride Novartis) Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

icandra (previously vildagliptin / metformin hydrochloride novartis)

novartis europharm limited - vildagliptin, kvarta stutt og long-term - sykursýki, tegund 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 fyrir tiltæk gögn um mismunandi samsetningar).

Femar Filmuhúðuð tafla 2,5 mg Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

femar filmuhúðuð tafla 2,5 mg

novartis healthcare a/s - letrozolum inn - filmuhúðuð tafla - 2,5 mg